Projections of the current and future disease burden of Hepatitis C virus infection in Malaysia

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  McDonald, Scott A ^a,b,c   Dahlui, Maznah ^a   Mohamed, Rosmawati ^a   Naning, Herlianna ^a   Shabaruddin, Fatiha Hana ^a   Kamarulzaman, Adeeba ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MORTALITY; POPULATION RESEARCH; PREVALENCE; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT; ACUTE DISEASE; BIOLOGICAL MODEL; CALIBRATION; COST OF ILLNESS; DISEASE COURSE; HEPACIVIRUS; PHYSIOLOGY; PROBABILITY; SUBSTANCE ABUSE; VIROLOGY;

HEPATITIS C VIRUS;

ACUTE DISEASE; CALIBRATION; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALAYSIA; MODELS, BIOLOGICAL; PROBABILITY; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84934918847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128091     Document Type: Article

References (52)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29: 74-81. doi: 10.1111/j.1478-3231.2008.01934.x PMID: 19207969
2. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatol. 2013; 57: 1333-1342. doi: 10.1002/hep.26141 PMID: 23172780
3. World Health Organisation. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: WHO; 2012.
4. De Angelis D, Sweeting M, Ades AE, Hickman M, Hope V, Ramsay M. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Meth Med Res. 2009; 18: 361-379.
5. Presanis AM, De Angelis D, Hagy A, Reed C, Riley S, Cooper BS, et al. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med. 2009; 6: e1000207. doi: 10.1371/journal.pmed.1000207 PMID: 19997612
6. McDonald SA, Mohamed R, Dahlui M, Naning H, Kamarulzaman A. Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Inf Dis. 2014; 14:564.
7. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91: 228-235. PMID: 17669601
8. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME.The burden of hepatitis C in England. J Viral Hepat. 2007; 14: 570-6. PMID: 17650291
9. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 2003; 9: 331-338. PMID: 12682882
10. Hutchinson SJ, Bird SM, Goldberg DJ. Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications. Expert Rev Pharmacoecon Outcomes Res. 2006; 6: 627-639. doi: 10.1586/14737167.6.6.627 PMID: 20528488
11. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014; 21: 34-59. doi: 10.1111/jvh.12248 PMID: 24713005
12. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol. 2004; 40: 319-326. PMID: 14739105
13. Ministry of Health Malaysia. Malaysia 2014 country response to HIV/AIDS. Reporting period: January 2013 to December 2013. Kuala Lumpur: Ministry of Health; 2014.
14. Department of Statistics Malaysia. Population Statistics and Basic Demographic Characteristics Report 2010. http://www.statistics.gov.my/portal/index.php?option = com-content&id=1215. Accessed 25 June 2014.
15. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007; 14: 107-115. PMID: 17244250
16. Ministry of Health Malaysia. Malaysia 2012 UNGASS country progress report. Kuala Lumpur: Ministry of Health; 2012.
17. Vicknasingam B, Narayanan S, Navaratnam V. The relative risk of HIV among IDUs not in treatment in Malaysia. AIDS Care 2009; 21: 984-991. doi: 10.1080/09540120802657530 PMID: 20024754
18. Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction. 2012; 107: 614-623. doi: 10.1111/j.1360-0443.2011.03654.x PMID: 21919987
19. Innes H, Goldberg D, Dusheiko G, Hayes P, Mills PR, Dillon JF, et al. Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. J Hepatol. 2014; 60: 1118-1126. doi: 10.1016/j.jhep.2014.01.020 PMID: 24509410
20. Sypsa V, Touloumi G, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat. 2004; 11: 366-374. PMID: 15230860
21. Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.J Clin Epidemiol. 2006; 59: 144-152. PMID: 16426949
22. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, et al. A population-based record-linkage study of mortality in hepatitis C diagnosed persons with and without HIV coinfection in Scotland. Stat Meth Med Res. 2009; 18: 271-283.
23. Murray CJL. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994; 72: 429-445. PMID: 8062401
24. Murray CJL, Lopez AD. The Global Burden of Disease - A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
25. Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, Haagsma JA, Praet N, Dorny P, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Pub Health. 2014; 59: 565-569.
26. Kretzschmar M, Mangen M-J, Pinheiro P, Jahn B, Fèvre EM, Longhi S, et al. New methodology for estimating the burden of infectious diseases in Europe. PLoS Med. 2012; 9: e1001205. doi: 10.1371/journal.pmed.1001205 PMID: 22529750
27. Stouthard ME, Essink-Bot ML, Bonsel GJ, Barendregt JJM, Kramers PGN, van de Water HPA, et al. Disability weights for diseases in the Netherlands. Amsterdam: Inst. Sociale Geneeskunde, University of Amsterdam; 1997.
28. World Health Organisation. Global Health Observatory Data Repository [http://apps.who.int/gho/data/?theme = main&vid=60990]. Accessed 25 June 2014.
29. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
30. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: Evolution, critique and future directions. Stat Med. 2009; 28: 3049-3067. doi: 10.1002/sim.3680 PMID: 19630097
31. Thomas A, O'Hara B, Ligges U, Sturtz S. Making BUGS Open. R News. 2006; 6: 12-17. PMID: 17392586
32. Department of Statistics Malaysia. Yearbook of Statistics Malaysia 2007. Kuala Lumpur: Department of Statistics; 2007.
33. Department of Statistics Malaysia. Yearbook of Statistics Malaysia 2009. Kuala Lumpur: Department of Statistics; 2009.
34. Department of Statistics Malaysia. Statistics Yearbook Malaysia 2012. Kuala Lumpur: Department of Statistics; 2012.
35. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45: 529-538. PMID: 16879891
36. Kirby Institute.Australian NSP Survey National Data Report 1995-2010. Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales; 2011.
37. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Tech Assess. 2007; 11: 1-228.
38. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Tech Assess. 2011; 15: 1-210.
39. Brady B, Siebert U, Sroczynski G, Murphy G, Husereau D, Sherman M. Clinical and cost-effectiveness of interferon-based therapies for chronic hepatitis C virus infection. Technology Overview no 27. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
40. Lancet The. Hepatitis C: Only a step away from elimination? Lancet. 2015; 385: 1045. doi: 10.1016/S0140-6736(15)60584-0 PMID: 25797543
41. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatol. 2014; 59: 1246-1249.
42. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015; 162: 407-419. doi: 10.7326/M14-1152 PMID: 25775313
43. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman B, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015. doi: 10.7326/M14-1313
44. Armstrong GL.Commentary: Modelling the epidemiology of hepatitis C and its complications. Int J Epidemiol. 2003; 32: 725-726. PMID: 14559739
45. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22: 1979-1991. doi: 10.1097/QAD.0b013e32830e6d51 PMID: 18784461
46. Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Inf Dis. 2013; 57: 1014-1020. doi: 10.1093/cid/cit377 PMID: 23728143
47. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatol. 2012; 55: 49-57.
48. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat. 2014; 22: 1-5.
49. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13: 34-41. PMID: 16364080
50. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006; 10: 1-113. PMID: 17134596
51. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatol. 2005; 42: 711-723.
52. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol. 1997; 112: 463-472.